If this years results hold up I'm almost sure we will have one or more partners for specific indications rather than for a drug or entire platform. That's the direction things are currently headed. I don't know if there is any interest in a total Co. buyout by BP but that is not the best way to maximize shareholder return at this stage of development IMO.
News 
Market Data 
Discover 
